Overview
Biotts is a biotech company specializing in transdermal drug delivery systems, utilizing their proprietary Multifunctional Transdermal Carrier Y (MTC-Y™) technology. This technology enables the transdermal delivery of larger molecules, such as peptides and proteins, up to 6,000 Da, improving bioavailability and offering a needle-free administration alternative. Biotts develops its own transdermal drug products and collaborates with the pharmaceutical industry for technical development.
Financials
The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
News
De-risking the clinical pathway: Biotts provides translational validation for the $13B chronic wound care market
The global chronic wound care market is currently valued at over $13 billion, driven by an urgent clinical need for more effective treatments for diabetic foot ulcers, pressure sores, and hard-to-heal surgical wounds. Despite the massive commercial potential, pharmaceutical pipelines in this space historically face high attrition rates, largely due to poor translational models that fail to accurately predict human clinical outcomes.
Data in Frontiers in Pharmacology shows Biotts’ proprietary platform significantly outpaces standard antibiotic therapy in chronic wound care
Biotts has achieved a significant scientific and commercial milestone with the publication of new peer-reviewed data in the prestigious journal Frontiers in Pharmacology.
Biotts’ New Study on Transdermal Lidocaine and Tetracaine in Pharmaceutics
Biotts publishes peer-reviewed research in Pharmaceutics (MDPI) validating MTC-Y™ technology for transdermal delivery of lidocaine and tetracaine.
Biotts Granted US Patent for MTC-Y Transdermal Carrier Technology
Biotts has been granted US Patent No. 12,478,679 B2 for its MTC-Y transdermal carrier technology. The patent was issued by the USPTO on 25 November 2025.
Biotts at BioJapan 2025 – Bringing Polish Transdermal Innovation to Asia
Biotts represented Polish transdermal innovation at BioJapan 2025 in Yokohama, Japan - Asia's premier bio-industry partnering event. Read about our experience.
Enhance Your R&D with GMP-Certified Biotts Solutions
At Biotts, we offer tailored, GMP-compliant research and development services specifically designed to meet the rigorous needs of pharmaceutical, biotechnology, cosmetics, and dietary supplements companies. Our multidisciplinary team, supported by advanced GMP-certified laboratories, ensures comprehensive project support from initial formulation through to analytical validation.
Industry
Bank accounts
Registered as a VAT taxpayer on 2018-03-02. Active
02 1090 1522 0000 0001 4322 7798- 68 1090 1522 0000 0001 5634 8091
- 12 1090 2473 0000 0001 3587 4256
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Aug 21, 2026 | Commercial Companies Code notice | |
| Jul 1, 2026 | Shareholders' meeting convened | |
| Jun 13, 2019 | Commercial Companies Code notice |
Public aid
10 public aid cases recorded, with a total value of $4,589,696.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 10, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | — | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Sep 30, 2023 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | — | Fundacja Instytut Studiów Wschodnich | |
| Nov 7, 2022 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | — | Dolnośląska Agencja Rozwoju Regionalnego S.A. |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-06-15 | Przygotowanie przez Biotts S.A. projektu o Eurogrant planowanego do realizacji w ramach programu EIC Pre-accelerator - Widening (HORIZON-WIDERA-2025-02) | $17,431 | Fundusze Europejskie dla Nowoczesnej Gospodarki |
Tenders
3 tenders recorded as contractor, with a total value of $95,400.
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Apr 20, 2026 | Usługa badawcza polegająca na przetestowaniu in vivo eliminacji gronkowca złocistego ze skóry zwierząt za pomocą enzybiotyku Aurezyna R oraz usługa badawcza polegająca na opracowaniu metody pomiaru... | $45,048 | Instytut Medycyny Doświadczalnej i Klinicznej Im. Mirosława Mossakowskiego Pan | |
| Oct 8, 2025 | Opracowanie prototypu formulacji | $49,855 | Instytut Medycyny Doświadczalnej i Klinicznej Im. Mirosława Mossakowskiego Pan | |
| Jul 25, 2025 | U/12/2025/B Organizacja i przeprowadzenie szkoleń wyjazdowych dla Wydziału Chemii i Farmacji | $497 | Uniwersytet Opolski |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
Each member of the management board is entitled to represent the company independently.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Paweł Czesław Biernat (51)  | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). |
Beata Turlejska (48) | Natural person holding a senior management position (AML Act art. 2(2)(1)(a) indent 5). |
Subsidiaries
| Name | Share value | Stake | |
|---|---|---|---|
NGD Pharmasp. z o.o. | 13,884.39 USD | 100% |
Competitors
| Name | Revenue | Website | |
|---|---|---|---|
| BioceltixS.A. | $616,315.97 | bioceltix.com | |
| FamicordtxS.A. | $589,673.84 | famicordtx.com | |
| OrthogetS.A. | $532,980.53 | orthoget.com | |
| VET Cell Techsp. z o.o. | $483,439.81 | vetcelltech.com | |
| MedisensonicS.A. | $362,572.63 | medisensonic.com | |
| PolbionicaS.A. | $356,011.70 | polbionica.com | |
| Green ZebrasS.A. | $328,658.91 | whygreenzebras.pl | |
| BiocamS.A. | $327,799.68 | biocam.ai | |
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | |
| FcbiotechS.A. | $246,877.92 | fcbiotech.pl |
Change history
| Date | Event |
|---|---|
| 2026-03-13 | Share capital change (311,385.00 PLN → 312,169.00 PLN) |
| 2025-08-12 | Share capital change (290,615.00 PLN → 311,385.00 PLN) |
| 2025-05-23 | Share capital change (287,060.00 PLN → 290,615.00 PLN) |
| 2024-12-23 | Share capital change (286,923.00 PLN → 287,060.00 PLN) |
| 2024-08-30 | Share capital change (281,057.00 PLN → 286,923.00 PLN) |
FAQ
Last updated: 2026-10-02